Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 124

1.

Optimizing ribavirin exposure by therapeutic drug monitoring improves treatment response in patients with chronic hepatitis C genotype 1.

Stickel F, Worni M, Pache I, Moradpour D, Helbling B, Borovicka J, Gerlach TJ.

Am J Gastroenterol. 2013 Jul;108(7):1176-8. doi: 10.1038/ajg.2013.140. No abstract available.

PMID:
23821001
[PubMed - indexed for MEDLINE]
2.

Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.

[No authors listed]

Ann Intern Med. 2013 Dec 3;159(11):I-14. doi: 10.7326/0003-4819-159-11-201312030-00001. No abstract available.

PMID:
24297207
[PubMed - indexed for MEDLINE]
3.

Predictors of sustained virologic response in hepatitis C genotype 4: beyond the usual suspects.

Abdo AA, Sanai FM.

Ann Saudi Med. 2009 Jan-Feb;29(1):1-3. No abstract available.

PMID:
19139625
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Ribavirin in chronic hepatitis C: past and future.

Loustaud-Ratti V, Rousseau A, Marquet P, Denis F, Alain S.

Expert Rev Anti Infect Ther. 2009 Apr;7(3):249-53. doi: 10.1586/eri.09.5. No abstract available.

PMID:
19344238
[PubMed - indexed for MEDLINE]
5.

Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment.

Yu JW, Sun LJ, Zhao YH, Kang P, Yan BZ.

Int J Infect Dis. 2011 Nov;15(11):e740-6. doi: 10.1016/j.ijid.2011.05.018. Epub 2011 Jul 30.

PMID:
21803628
[PubMed - indexed for MEDLINE]
Free Article
6.

Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.

Bonardi R, Tabone M, Manca A, Pellicano R, Ciancio A, Rizzetto M.

Biomed Pharmacother. 2011 Jul;65(4):303-6. doi: 10.1016/j.biopha.2011.03.004. Epub 2011 May 30.

PMID:
21723079
[PubMed - indexed for MEDLINE]
7.

Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin.

Oze T, Hiramatsu N, Song C, Yakushijin T, Iio S, Doi Y, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Inoue A, Imai Y, Hayashi E, Kato M, Miyazaki M, Hosui A, Miyagi T, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Hayashi N, Takehara T.

J Gastroenterol. 2012 Mar;47(3):334-42. doi: 10.1007/s00535-011-0498-3. Epub 2011 Nov 23.

PMID:
22109353
[PubMed - indexed for MEDLINE]
8.

[Individualization of antiviral treatment of chronic hepatitis].

Konstantinov DIu, Konstantinova EA, Strebkova EA, Popova LL, Suzdal'tsev AA.

Eksp Klin Gastroenterol. 2013;(6):29-34. Russian. No abstract available.

PMID:
24772857
[PubMed - indexed for MEDLINE]
9.

Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4.

Urquijo JJ, Diago M, Boadas J, Planas R, Solá R, Del Olmo JA, Crespo J, Erdozaín JC, Antón MD, Arocena C, Suarez D, Giné J, Barrera JM, Gracia-Samaniego J, Perez R, Dalmau B, Montoro M.

Ann Hepatol. 2013 Jan-Feb;12(1):30-5.

PMID:
23293191
[PubMed - indexed for MEDLINE]
10.

Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b.

Hashimoto Y, Ochi H, Abe H, Hayashida Y, Tsuge M, Mitsui F, Hiraga N, Imamura M, Takahashi S, Nelson Hayes C, Ohishi W, Kubo M, Tsunoda T, Kamatani N, Nakamura Y, Chayama K.

J Med Virol. 2011 Jun;83(6):981-8. doi: 10.1002/jmv.22028.

PMID:
21503910
[PubMed - indexed for MEDLINE]
11.

Pegylated interferon treatment in HCV genotype 2 and 3 patients refractory to conventional interferon.

Aziz S.

J Coll Physicians Surg Pak. 2012 Oct;22(10):615-6. doi: 10.2012/JCPSP.615616. No abstract available.

PMID:
23058141
[PubMed - indexed for MEDLINE]
12.

Plasma ribavirin trough concentrations during treatment of chronic hepatitis C in genotype-1 patients.

Muñoz-de-Rueda P, Ruiz-Extremera A, Candel JM, Quiles R, Martín AB, Diago M, Andrade R, Navarro JM, Gila A, León J, Carazo A, Quintero D, Salmerón J.

J Clin Gastroenterol. 2012 Apr;46(4):328-33. doi: 10.1097/MCG.0b013e318237123f.

PMID:
22105181
[PubMed - indexed for MEDLINE]
13.

Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.

Labarga P, Barreiro P, da Silva A, Guardiola JM, Rubio R, Aguirrebengoa K, Miralles P, Portu J, Téllez MJ, Morano L, Castro A, Pineda JA, Terrón A, Hernández-Quero J, Mariño A, Ríos MJ, Echeverría S, Asensi V, Vispo E, Soriano V; PERICO Study Group.

J Infect Dis. 2012 Sep 15;206(6):961-8. Epub 2012 Jul 17.

PMID:
22807523
[PubMed - indexed for MEDLINE]
Free Article
14.

Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT.

Al-Ali J, Siddique I, Varghese R, Hasan F.

Ann Hepatol. 2012 Mar-Apr;11(2):186-93.

PMID:
22345335
[PubMed - indexed for MEDLINE]
15.

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.

Itokawa N, Atsukawa M, Tsubota A, Kondo C, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Iwakiri K, Sakamoto C.

J Gastroenterol Hepatol. 2013 Mar;28(3):443-9. doi: 10.1111/jgh.12039.

PMID:
23173698
[PubMed - indexed for MEDLINE]
16.

Rapid, early and sustained virological responses in a cohort of Irish patients treated with pegylated interferon and ribavirin for chronic hepatitis C virus infection.

Sarwar S, Ryan EJ, Iqbal M, McCormick PA, O'Farrelly C, Hegarty J.

Ir J Med Sci. 2012 Mar;181(1):53-8. doi: 10.1007/s11845-011-0775-4. Epub 2011 Oct 29.

PMID:
22038749
[PubMed - indexed for MEDLINE]
17.

Sustained virological response after treatment in patients with chronic hepatitis C infection--a five year follow up.

Rahman MZ, Ahmed DS, Masud H, Parveen S, Rahman MA, Chowdhury MS, Barua R, Ishaque SM.

Bangladesh Med Res Counc Bull. 2013 Apr;39(1):11-3.

PMID:
23923405
[PubMed - indexed for MEDLINE]
18.

Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan.

Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Fukui H, Hijioka T, Katayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Hayashi E, Kato M, Hosui A, Miyagi T, Ishida H, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N.

J Gastroenterol. 2011 Aug;46(8):1031-7. doi: 10.1007/s00535-011-0409-7. Epub 2011 May 3.

PMID:
21538029
[PubMed - indexed for MEDLINE]
19.

Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.

Mach TH, Cieśla A, Warunek W, Janas-Skulina U, Cibor D, Owczarek D, Ciećko-Michalska I.

Pol Arch Med Wewn. 2011 Dec;121(12):434-9.

PMID:
22157768
[PubMed - indexed for MEDLINE]
Free Article
20.

Relative impact of ribavirin monitoring and HIV coinfection on sustained virological response in patients with chronic hepatitis C.

Piedoux S, Monnet E, Piroth L, Montange D, Royer B, Thevenot T, Kantelip JP, Di Martino V, Muret P; RibAct group.

Antivir Ther. 2011;16(8):1317-26. doi: 10.3851/IMP1920.

PMID:
22155913
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk